目的 探討松齡血脈康膠囊聯(lián)合非諾貝特膠囊治療糖尿病合血脂代謝異常的臨床療效。方法 選取2016年7月—2018年7月在南平市第一醫(yī)院就診的260例糖尿病合血脂代謝異常患者，隨機(jī)分為觀察組（n=130）和對照組（n=130）。對照組患者口服非諾貝特膠囊，200 mg/次，1次/d。觀察組在對照組基礎(chǔ)上給予松齡血脈康膠囊，3粒/次，3次/d。4周為1個療程，兩組患者均治療2個療程。觀察兩組患者的臨床療效，比較兩組的糖代謝指標(biāo)、血脂代謝指標(biāo)及不良反應(yīng)發(fā)生情況。結(jié)果 治療后，與對照組總有效率（80.00%）比較，觀察組總有效率（93.85%）顯著升高（P<0.05）。治療后，兩組空腹血糖（FBG）、餐后2 h血糖（2 hPG）、糖化血紅蛋白（HbA1c）和胰島素抵抗指數(shù)（HOMA-IR）水平均顯著低于治療前（P<0.05），且觀察組糖代謝指標(biāo)顯著低于對照組（P<0.05）。治療后，兩組總膽固醇（TC）、三酰甘油（TG）、高密度脂蛋白（HDL-C）和低密度脂蛋白（LDL-C）水平與治療前比較均顯著改善（P<0.05），且觀察組血脂代謝指標(biāo)顯著優(yōu)于對照組（P<0.05）。兩組不良反應(yīng)發(fā)生率比較差異無統(tǒng)計(jì)學(xué)意義。結(jié)論 松齡血脈康膠囊聯(lián)合非諾貝特膠囊可有效改善糖尿病合血脂代謝異?；颊叩难呛脱?，值得臨床推廣。

Objective To investigate the clinical effect of Songling Xuemaikang Capsules combined with Fenofibrate Capsules in treatment of diabetes mellitus with dyslipidemia. Methods Patients (260 cases) with diabetes mellitus and dyslipidemia in The Nanping First Hospital from July 2016 to July 2018 were randomly divided into observation group (n=130) and control group (n= 130). Patients in the control groups were po administered with Fenofibrate Capsules, 200 mg/time, once daily. Patients in the observation groups were treated with Songling Xuemaikang Capsules on the basis of control groups, 3 grains/time, three times daily. 4 weeks as one course, patients in two groups were treated for 2 courses. After treatment, the clinical effect in two groups was observed, and the glycometabolism indexes, blood lipid metabolism indexes, and adverse reactions between two groups were compared. Results After treatment, compared with the total effective rate in the control group (80.00%), the total effective rate in the observation group (93.85%) was significantly increased (P < 0.05). After treatment, the levels of FBG, 2 hPG, HbA1c, and HOMA-IR in two groups were significantly decreased (P < 0.05), and the glycometabolism indexes levels in the observation group was significantly lower than those in the control group (P < 0.05). After treatment, the levels of TC, TG, HDL-C, and LDL-C in two groups were significantly improved (P < 0.05), and the blood lipid metabolism indexes in the observation group was significantly better than those in the control group (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups. Conclusion Songling Xuemaikang Capsules combined with Fenofibrate Capsules can effectively improve blood gluose and lipid levels in patients with diabetes mellitus with dyslipidemia, which is worthy of clinical promotion.

R977

軍區(qū)醫(yī)學(xué)科技創(chuàng)新課題（14ms078）